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Polyfunctionalized stigmasterol derivatives, (22S,23S)-22,23-dihydroxystigmast-4-en-3-one (compound 1) and (22S,23S)-3𝛽-
bromo-5𝛼,22,23-trihydroxystigmastan-6-one (compound 2), inhibit herpes simplex virus type 1 (HSV-1) replication and spreading
in human epithelial cells derived from ocular tissues. Both compounds reduce the incidence and severity of lesions in a murine
model of herpetic stromal keratitis when administered in different treatment modalities. Since encephalitis caused by HSV-1 is
another immunopathology of viral origin, we evaluate here the antiviral effect of both compounds on HSV-1 infected nervous cell
lines as well as their anti-inflammatory action. We found that both stigmasterol derivatives presented low cytotoxicity in the three
nervous cell lines assayed. Regarding the antiviral activity, in all cases both compounds preventedHSV-1multiplicationwhen added
after infection, as well as virus propagation. Additionally, both compounds were able to hinder interleukin-6 and Interferon-gamma
secretion induced by HSV-1 infection in Neuro-2a cells. We conclude that compounds 1 and 2 have exerted a dual antiviral and
anti-inflammatory effect in HSV-1 infected nervous cell lines, which makes them interesting molecules to be further studied.
1. Introduction
Herpesviruses are present throughout the animal kingdom
having evolved over hundreds of millions of years with their
hosts. To date, at least eight distinct human herpesviruses
have been identified and, between them, herpes simplex
virus (HSV) is the most ubiquitous. A characteristic of all
herpesvirus infections, however, is their ability to establish
lifelong infections characterized by periods of latency fol-
lowed by reactivation.
For instance, the recurrent mucocutaneous infections
exerted byHSV are painful and socially concerning; however,
they are not the most serious manifestations of infection.
Since HSV is so prevalent, complications of recurrence have
a considerable medical burden on both immune competent
and immune compromised persons. These complications
include keratitis, hepatitis, pneumonia, esophagitis, and
encephalitis [1].
The morbidity caused by these acute and recurrent
infections produces much human suffering for which there
remains an unmet need for control by effective immunization
or antiviral therapy. To date, there has been little success with
HSV vaccines. Antiviral drugs such as acyclovir (ACV) have
been the mainstay of HSV therapy for three decades, with
outstandingly few adverse effects. However, viral resistance
has emerged as a potential problem which, together with the
eradication of latency, has not been solved yet.
Previously, we have reported that some polyfunctional-
ized stigmasterol derivatives have in vitro antiviral activity
with a broad spectrum of action. These synthetic com-
pounds not only inhibit the multiplication of RNA viruses,
such as Junin, Tacaribe, measles virus, and VSV, but also
restrain HSV-1 multiplication [2–4]. Particularly, we have
demonstrated that (22S,23S)-22,23-dihydroxystigmast-4-en-
3-one (compound 1) and (22S,23S)-3𝛽-bromo-5𝛼,22,23-
trihydroxystigmastan-6-one (compound 2) inhibit HSV-1
replication and spreading in human epithelial cells derived
from ocular tissues [5, 6]. Both compounds reduce the
incidence and severity of lesions in a murine model of HSV-1
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induced ocular disease when administered in different treat-
ment modalities [7]. This experimental model of ocular dis-
ease reproduces clinically and histologically the human her-
petic stromal keratitis (HSK), an immunopathology of viral
origin [8–10]. Furthermore, subsequent studies have revealed
that the stigmasterol derivatives hinder the production of
tumor necrosis factor alpha (TNF-𝛼) in a LPS-stimulated
murine macrophage cell line and modulate the secretion of
Interleukin-6 (IL-6) and TNF-𝛼 in HSV-1 infected corneal
and conjunctival cells, exerting an in vitro immunomodula-
tory effect [11, 12]. Hence, the improvement of HSK observed
could also be ascribed to their immunomodulatory action
[13].
One of the rare but devastating life-threatening diseases
caused by HSV is adult and neonatal encephalitis (HSVE).
Even though some therapies are available to treat patients
with HSVE, as well as several antiviral drugs having been
developed, outcomes still remain relatively poor [14]. Acy-
clovir treatment is effective in reducing mortality but is
less effective in dismissing morbidity. Kamei et al. [15] have
reported that the therapy combining acyclovir with corticos-
teroids appears to give a better outcome in adult patients
with HSVE. One pharmacological mechanism related to
corticosteroid in HSVE is the inhibition of proinflammatory
cytokines such as IL-6 [16].
Considering the urgent need for different therapeutic
options to combat acute and latentHSV infection in the brain,
we decided to study the effect of both stigmasterol derivatives
on HSV-1 replication in three nervous cell lines.
2. Materials and Methods
2.1. Cells, Viruses, and Treatment Solutions. Simian Vero
cells were grown in Eagle’s minimal essential medium sup-
plemented with 5% inactivated fetal bovine serum (FBS)
(MEM 5%) and 50 𝜇g/mL gentamycin. Human SH-SY5Y cell
line was grown in Dulbecco’s Modified Medium and Nutri-
ent Mixture F-12 (DMEM/F12) 1 : 1 mixture, supplemented
with 10% inactivated FBS (DMEM/F12 10%) and 50 𝜇g/mL
gentamycin. Rat PC-12 cell line was grown in DMEM/F12
supplementedwith 5% inactivated FBS, 10% inactivated horse
serum, and 50 𝜇g/mL gentamycin. Murine Neuro-2a cell line
was grown in DMEM/F12 10%, 50𝜇g/mL gentamycin, and
sodium pyruvate 5𝜇g/mL.
HSV-1 Cgal+ (HSV-1 Cgal) KOS strain was propagated
at low multiplicity on Vero cells. This system contains the
Escherichia coli lacZ reporter gene encoding 𝛽-galactosidase
under the control of a human cytomegalovirus promoter
and was kindly provided by Dr. Alberto Epstein (Universite´
Claude Bernard, Lyon, France).
The HSV-1 KOS wt strain was also propagated at low
multiplicity.
Compounds 1 and 2were dissolved in DMSO and diluted
with culture medium for testing. The maximum concentra-
tion of DMSO tested (1%) exhibited no toxicity.
2.2. Cytotoxicity Assay. Cell viability in the presence of
different concentration of the compound was determined
using the MTT assay [17]. The absorbance of each well was
measured on EurogeneticsMPR-A 4imicroplate reader using
a test wavelength of 570 nm and a reference wavelength of
630 nm. The CC
50
was defined as the concentration of the
compound that caused a 50% reduction in absorbance.
2.3. Antiviral Activity. Cells grown in 24-well plates were
infected with HSV-1 KOS and, after virus adsorption, treated
or not with the compounds. After 24 h of incubation at 37∘C,
supernatants were collected and titrated in Vero cells. Briefly,
Vero cells grown in 24-well plates were infected with serial
10-fold dilutions of viral yields and incubated for 1 h at 37∘C.
Residual inocula were replaced bymaintenancemediumwith
0.7% ofmethylcellulose. After 72 h of incubation at 37∘C, cells
were fixed with formaldehyde 10% and stained with Crystal
Violet, and plaque forming units were counted.
2.4. Measurement of 𝛽-Gal Activity. Cells grown in coverslips
inside 24-well plates were infected with HSV-1 Cgal. After
adsorption, inocula were eliminated and cells were covered
with MEM 1.5%. At 24 h after infection (p.i.), supernatants
were harvested and stored at −70∘C for titration, and cells
were stained in situ for 𝛽-gal [5]. Coverslips were mounted,
observed with an Olympus BX61 microscope, and pho-
tographed.
2.5. Indirect Immunofluorescence Assay. Cells monolayers
grown on glass coverslips inside 24-well plates were fixed
with methanol for 10min at −20∘C. After three washes
with PBS, coverslips were incubated with diluted primary
antibody for 30min at 37∘C and subjected to three additional
washes with PBS. Afterwards, cells were incubated with
secondary antibody for 30min at 37∘C. Finally, coverslips
were rinsed, mounted, and photographed with an Olympus
FB300 confocal microscope.
2.6. CytokineDetermination. Neuro-2a cells grown in 24-well
plates were infected with HSV-1 at a multiplicity of infection
(m.o.i.) of 1. After 24 hof incubation at 37∘Ccells supernatants
were harvested and cytokines were quantified. Murine IL-
6 and IFN-gamma were quantified by commercial ELISA
sets (BD OptEIATM, Becton Dickinson, USA) according to
manufacturer instructions.
2.7. Statistics. Data are presented as the means ± SD. Sta-
tistical significance was determined using Student 𝑡-test. A
𝑃 < 0.05 was considered significant.
3. Results
3.1. HSV-1 Replication Kinetics in Nervous Cell Lines. Prior
to the evaluation of the antiviral activity of the stigmasterol
derivatives, we analyzed the kinetics of HSV-1 multiplication
in three different cell lines.
Multistep kinetics were carried out in Neuro-2a, PC-
12, and SH-SY5Y cells grown in 24-well plates, which were
infected with HSV-1 strain KOS wt (m.o.i. = 1 PFU/cell). At
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24, 48, and 72 h p.i., supernatants were harvested and virus
yields were determined through a plaque assay in Vero cells.
As shown in Figure 1, HSV-1 replicated efficiently in these
cultures. By 24 h p.i., viral titres were considerably lower in
Neuro-2a cells, reaching a value of 105 PFU/mL, whereas a
value of 5 × 106 PFU/mL was obtained for PC-12 and SH-
SY5Y cells. By 48 h p.i., viral titres raised nearly two logs
in both cell types, while a slight decrease in Neuro-2a cells
was observed. In summary, PC-12 cells exhibited the highest
susceptibility to HSV-1 infection andNeuro-2a and SH-SY5Y
cells were also susceptible, reaching the maximum viral titres
at 72 h (Figure 1). Interestingly, none of the three infected
nervous cell lines exhibited cytopathic effect even after 72 h
p.i. Taking into account previous findings and according
to these results, we established 24 h p.i. and m.o.i. of 1 as
parameters for HSV-1 infection in the three cell lines [5, 6].
3.2. Cytotoxicity of Compounds 1 and 2 in Nervous Cell
Lines. Fifty percent cytotoxic concentration (CC
50
) for PC-
12, Neuro-2a, and SH-SY5Y cells was determined. Com-
pounds 1 and 2 were added to confluent nongrowing cells
in concentrations ranging from 1 to 144 𝜇M and from 1 to
129 𝜇M, respectively, and, after 24 h incubation at 37∘C, a
MTT colorimetric assay was performed.
CC
50
values of compounds 1 and 2 obtained in SH-SY5Y
cells were 77.2 and 70𝜇M, respectively (Figure 2(c)), similar
to that previously reported for compound 1 in IOBA-NHC
cells (71.2𝜇M) [6]. In the case of Neuro-2a (Figure 2(b))
and PC-12 (Figure 2(a)) cells treated with compound 1, CC
50
values were even higher (80.4 and >144 𝜇M, resp.). On the
other hand, CC
50
values estimated for compound 2 ranged
from 65.2 in Neuro-2a cells to >129 𝜇M in PC-12 cells, and
both were lower than that previously reported in IOBA-NHC
cells (>277𝜇M) (Figure 2) [5].
Hence, compound 1 as well as compound 2 displayed a
low cytotoxicity for the three nervous cell lines assayed.
3.3. Anti-HSV Activity of Compounds 1 and 2 in Neuro-
2a, PC-12, and SH-SY5Y Cells. Taking into account the
broad spectrum of antiviral activity already reported for
compounds 1 and 2 [2–6, 18, 19] we decided to study their
anti-HSV-1 effect in nervous cell lines, which were infected
with two different strains of HSV-1, KOS wt strain, and KOS
Cgal strain.
To assay the antiviral activity of compounds 1 and 2, we
chose concentrations of 10 𝜇M and 5 𝜇M, respectively, which
were, at least, seven times lower than the corresponding
CC
50
values found (Figure 2). Neuro-2a, PC-12, and SH-
SY5Y cells grown in 24-well plates were infected with HSV-1
KOS wt strain at m.o.i. of 1. After 24 h of incubation at 37∘C,
supernatants were collected and titrated in Vero cells.
HSV-1 Cgal strain multiplied more efficiently
than KOS wt strain in Neuro-2a and SH-SY5Y cells,
whereas viral titre was significantly lower in PC-12 cells
(Figures 3(a), 3(b), and 3(c)).
Both compounds restrained HSV-1 KOS wt multipli-
cation since viral titres decreased in around 1-2 logs with
respect to viral titres obtained from untreated infected cells.
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Figure 1: Effect of stigmasterol derivatives 1 and 2 on HSV-1
multiplication. PC-12 (square), Neuro-2a (triangle), and SH-SY5Y
cells (circle) were infected with HSV-1 KOS (m.o.i.: 1) and incubated
for 1 h at 37∘C. After adsorption, cells were covered with DMEM/F12
2%. At 24, 48, and 72 h after infection supernatants were harvested
and viral titres were determined by plaque assay. Data are mean
values from two separate experiments ± SD.
Compound 2was more efficient than compound 1 to restrain
HSV-1 yield in the three nervous cell lines tested, reaching
an inhibition of nearly 2 logs in SH-SY5Y cells (Figures 3(a),
3(b), and 3(c)).Thus, both compounds preventedHSV-1 KOS
wt multiplication in the three nervous cell lines used when
added after infection.
We also found that recombinant HSV-1 Cgal was able to
multiply in PC-12, Neuro-2a, and SH-SY5Y cells and, regard-
ing the antiviral activity, both compounds hindered HSV-
1 Cgal replication in all cases (Figures 3(a), 3(b), and 3(c)).
Compounds 1 and 2 caused 1-2 log reduction in viral yields
regardless of the virus strain used.
We have previously reported that compounds 1 and 2
inhibit HSV-1 propagation in IOBA-NHC cells [5, 6]. To
investigate the effect of both compounds on viral propaga-
tion, PC-12, Neuro-2a, and SH-SY5Y cells grown in coverslips
inside 24-well plates were infected with HSV-1 Cgal (m.o.i.
= 1) and, then, treated with control media, 10 𝜇M of 1 and
5 𝜇M of 2. After 24 h incubation at 37∘C, cells were stained
in situ for 𝛽-gal. In the absence of compounds, stained
cells clustered in characteristic HSV-1 foci were observed
(Figure 4), whereas all infected cells treated with either 1 or
2 exhibited only scattered stained cells (Figure 4). Therefore,
both compounds would prevent HSV-1 Cgal spreading in all
nervous cell lines assayed when added after infection.
To corroborate these results, an indirect immunofluo-
rescence was performed. For that purpose, Neuro-2a cells
monolayers grown in coverslips inside 24-well plates were
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Figure 2: Cytotoxic effect of compounds 1 and 2 in three nervous cell lines. (a) PC-12, (b) Neuro-2a, and (c) SH-SY5Y cells monolayers were
incubated in the presence of different concentrations of compounds 1 and 2. After 24 h of incubation at 37∘C cell viability was determined
by the MTT assay. The CC
50
was defined as the concentration of the compound that caused a 50% reduction in cell viability. Data are mean
values from four separate experiments.
infected with HSV-1 KOS (m.o.i. = 1) and then treated with
control media, 10 𝜇M of 1 and 5 𝜇M of 2. After 24 h of
incubation at 37∘C, supernatants were removed and cells were
washed and fixed as described in Materials and Methods.
Cells were incubated with mouse monoclonal antibodies
anti-gD of HSV-1 and revealed with anti-mouse Fluo-
roLinkTM CyTM3 antibodies. The inhibition of viral spread
caused by both compounds shown in Figure 5 confirmed
the restriction of HSV-1 propagation previously observed
(Figure 4).
3.4. Anti-Inflammatory Effect of Compounds 1 and 2 in HSV-
1-Infected Neuro-2a Cells. We have previously reported that
compound 1 stimulates anti-inflammatory molecules and
inhibits proinflammatory factors in macrophages activated
with a nonviral stimulus, suggesting an immunosuppressive
action over inflammatory cells [13]. On the other hand,
compound 2 increases IL-6 levels in human epithelial cells
infected with HSV-1 [12]. Hence, we determined cytokine
levels in HSV-1 KOS-infected Neuro-2a cells after treatment
with both compounds, by ELISA. For that purpose, we used
those supernatants inwhich the antiviral effect of compounds
1 and 2 was found (Figure 3(b)). IL-6 and IFN-𝛾 secretion
reached 659.6 ± 14.8 pg/mL and 154.7 ± 7.2 pg/mL in HSV-
1 infected control cells, respectively. IL-6 levels were reduced
in 46.2% (355.4 ± 10.9 pg/mL, 𝑃 < 0.001) and 41.1% (388.2 ±
11.4 pg/mL, 𝑃 < 0.001) when infected cells were treated
with compounds 1 and 2, respectively. IFN-𝛾 levels dropped
to 72.3 ± 4.9 pg/mL (𝑃 < 0.006) (53.3%) and to 53 ±
4.2 pg/mL (𝑃 < 0.001) (65.7%) with respect to untreated
infected cells after treatment with 1 and 2. Thus, compounds
1 and 2might display an anti-inflammatory activity in HSV-
1-infected Neuro-2a cells.
4. Discussion
Many viruses of public health significance may cause disease
by triggering an immunopathology in which the damage is
produced by the host inflammatory response elicited by the
virus [20].
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Figure 3: Effect of compounds 1 and 2 on HSV-1 virus yield reduction. (a) PC-12, (b) Neuro-2a, and (c) SH-SY5Y cells were infected with
HSV-1 KOS (black bars) and HSV-1 Cgal (grey bars) and incubated for 1 h at 37∘C. Then, cells were covered with DMEM/F12 2% or media
containing 10𝜇Mof compound 1 and 5 𝜇Mof compound 2. After 24 h supernatants were harvested and viral titres were determined by plaque
assay. Bars show average of two replicates ± SD. ∗𝑃 < 0.05, with respect to untreated infected cells.
In the general population, HSV is highly prevalent (more
than 70% after age of 50). This virus persists latently in the
peripheral nervous system and periodically reactivates with
production of active virus. The pathogenic mechanisms of
HSV-1 at the central nervous system (CNS) are not well
known.The virus enters the brain and infects neurons, where
recurrent reactivations of HSV in CNS of adult people could
happen [21, 22]. On the other hand, HSVE is a rare but very
severe acute infection of the CNS. Brain inflammation due to
infection is associated with the activation of the local innate
immune system. This could be a crucial mechanism leading
to the neuronal damage, as it was also described in the case
of HSK, where a chronic inflammatory reaction in response
to viral reactivation in the eye may lead to vision impairment
and even blindness [8–10, 23].
Although intravenous ACV blocks viral replication and
significantly reduces the mortality associated with HSVE,
many infected patients still suffer from severe neurological
sequelae [24]. In turn, though progression of human HSK is
not prevented by ACV, treatment of HSK also includes ACV
to mitigate viral reactivation due to the immunosuppression
caused by corticosteroids, which are supplied to alleviate the
symptoms of disease [25].
Corticosteroids may be also beneficial in HSVE for
decreasing the activation of several inflammatory pathways
even though their adverse side effects are well known [26].
It was reported that combined therapy using both ACV and
corticosteroids can achieve a better outcome in adult patients
with HSVE as well as reducing the progression of inflamma-
tion during HSK [10, 15]. The healing effect of compounds
1 and 2 on the evolution of HSV-1-induced ocular disease in
mice reveals their dual effect, antiviral and anti-inflammatory
[5, 6].
The present study clearly demonstrates that stigmasterol
derivatives 1 and 2 have inhibited HSV-1 multiplication
and propagation in nervous cell lines of different origin
(Figures 3, 4, and 5), which is consistent with the already
reported antiherpetic activity observed in other cell lines
[2, 5, 6, 18, 19].
On the other hand, the anti-inflammatory effect of the
compounds varied depending upon cell substrate. Com-
pound 1 does not reduce TNF-𝛼 and IL-6 levels in HSV-
1-infected epithelial cells, whereas compound 2 inhibits
6 BioMed Research International
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Figure 4: Effect of compounds 1 and 2 onHSV-1 propagation. (a) PC-12, (b) Neuro-2a, and (c) SH-SY5Y cells monolayers grown in coverslips
inside 24-well plates were infected with HSV-1 Cgal and incubated for 1 h at 37∘C. Then, cells were covered with DMEM/F12 2% or media
containing 10𝜇M of compound 1 and 5 𝜇M of compound 2. After incubation for 24 h, cells were stained in situ for 𝛽-gal. Cgal: HSV-1 Cgal
infected-untreated cells; Cgal+1: HSV-1 Cgal infected 1-treated cells; Cgal+2: HSV-1 Cgal infected 2-treated cells. Magnification: 40x.
TNF-𝛼 in IOBA-NHC cells and increases IL-6 levels in
HSV-1-infected IOBA-NHC and HCLE cells [12] (Miche-
lini, personal communication). Furthermore, many overex-
pressed and repressed genes associated with innate immune
responses and inflammatory processes have been detected
in HSV-1-infected epithelial cells and activated macrophages
treated with compound 1, by means of RNAmicroarrays [13].
It is well-known that IL-6 has mainly proinflammatory
activity and plays an important role in inflammatory pro-
cesses in the CNS [16, 27, 28]. Thus, an increased expression
of IL-6 mRNA in brain tissue of mice infected with HSV was
shown during the first three weeks after infection [27]. In fact,
a significant increase of IL-6 concentration in CSF of patients
with HSVE was also observed [16, 28, 29].
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Figure 5: Effect of compounds 1 and 2 on HSV-1 KOSmultiplication in three nervous cell lines. Neuro-2a cells grown in coverslips inside 24-
well plates were infected with HSV-1 KOS wt and incubated for 1 h at 37∘C.Then, cells were covered with DMEM/F12 2% or media containing
10𝜇M of compound 1 and 5 𝜇M of compound 2. After 24 h p.i., cells were fixed with methanol and HSV-1 gD localization was done by IFI
staining. (a) Control cells; (b) mock-infected cells treated with compound 1, (c) mock-infected cells treated with compound 2, (d) HSV-
1 KOS infected cells, (e) HSV-1 KOS infected cells treated with compound 1, and (f) HSV-1 KOS infected cells treated with compound 2.
Magnification: 40x.
IFN-𝛾 is also involved in the development of CNS
pathologies since it enhances the function of microglia by
increasing the production of TNF-𝛼, NO, and free radicals,
which play critical roles in the progress of inflammatory
demyelination and neuronal degeneration [30].
Herein, our findings clearly indicate that compounds
1 and 2 have been able to inhibit the secretion of IL-6
and IFN-𝛾 induced by HSV-1 KOS wt infection of Neuro-
2a cells. Although the anti-inflammatory effect of com-
pounds 1 and 2 observed may be ascribed to their anti-
herpetic activity, we have reported that both compounds
are able to reduce IL-6 secretion in macrophages induced
with a nonviral stimulus, in a dose-dependent manner
[12].
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In an effort to reduce neuronal damage secondary to host
inflammatory response, cytokine modulation is an avenue
that has been proposed for the treatment of HSVE. Thus,
the effect of glucocorticoids was evaluated in a mouse model
of HSVE and revealed that modulating the innate immune
response in a timely manner could prevent neurological
damage and mortality [31].
Although compounds 1 and 2 showed a structural simil-
itude with the commercial anti-inflammatory glucocorticoid
dexamethasone, none of themwas able to bind glucocorticoid
receptors (GR) or induce a glucocorticoid activity via GR
activation (Michelini, personal communication). Thus, they
would be activating a different signaling pathway from that
of glucocorticoids, exerting their anti-inflammatory activity
through a different mechanism of action. This finding con-
stitutes an advantage in the use of these compounds over
glucocorticoids because they would not exert the known
undesirable side effects of the latter.
5. Conclusions
It is the first time that compounds 1 and 2 prove to have
a significant antiviral and anti-inflammatory effect in HSV-
1 infected nervous cell lines from different sources. Taking
into account that compound 1 has been recently patented
as a compound showing anti-inflammatory and antiviral
activities to treat HSK, it deserves to be further studied as a
potential tool to limit CNS diseases caused by HSV.
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